In association withPhilips
We may think of artificial intelligence (AI) in health care in terms of scientific advances, such as a cure for cancer or a science-fiction tricorder-like device. But in the real world, AI is making its initial impact in workflow and administrative tasks. That’s not to say AI technologies aren’t being used for genuinely exciting work in radiology, drug discovery, or to flag high-risk patients in covid-19 analysis.
A new Rx: AI for operations in health care
This content was produced by Insights, the custom content arm of MIT Technology Review. It was not written by MIT Technology Review’s editorial staff.
And the data shows it: according to a recent MIT Technology Review Insights survey of 1,004 AI experts, the top three uses for AI in health care are in quality control (60%), customer care and support (44%), and monitoring and diagnostics (42%). The importance of quality control in health care is obvious—better medicines and diagnostics help everyone from doctors to patients to pharmaceutical and insurance companies. Some might think that putting resources into the health-care back office is a cop-out. After all, isn’t the point of technology to save lives? But attention to “paperwork” by health-care technologists and vendors is a good thing.
Download the full report.
This scientist now believes covid started in Wuhan’s wet market. Here’s why.
How a veteran virologist found fresh evidence to back up the theory that covid jumped from animals to humans in a notorious Chinese market—rather than emerged from a lab leak.
The US crackdown on Chinese economic espionage is a mess. We have the data to show it.
The US government’s China Initiative sought to protect national security. In the most comprehensive analysis of cases to date, MIT Technology Review reveals how far it has strayed from its goals.
What Europe’s new covid surge means—and what it doesn’t
New restrictions are coming into place across Europe as covid cases rise again. But there are several reasons why a new wave is happening.
The China Initiative’s first academic guilty verdict raises more questions than it answers
Observers hoped that the trial of the prominent Harvard professor Charles Lieber would provide some clues into the future of the Department of Justice’s campaign against Chinese economic espionage.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.